The arithmetic behind every identity confirmation, worked in full
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
Priya Ramanathan, PharmD
Page 6 of 7 of this archive, newest first.
Archive — page 6
131 piecesWhat the tirzepatide schedule assumes about a person it has never met
We work the arithmetic out in full, because it is arithmetic and it is short.
Dose-limiting: a definition worth being strict about
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
The limits of mechanism: why receptor data will not tell you who responds
A catalogue of open questions, with an assessment of how likely each is to be resolved.
The convention nobody explains before handing over the vial
Dead space in the needle hub is a real and calculable loss, and it matters more at small volumes than anybody expects.
A missed dose, modelled: what happens to liraglutide concentrations over the following fortnight
Half-life, accumulation ratio and time to steady state are three separate quantities, and confusing them produces most of the bad advice in circulation.
A schedule that bends does not break
Nausea and gastric delay attenuate over weeks at an unchanged dose. That single physiological fact is the entire justification for holding.
What STEP 4 and SURMOUNT-4 actually established
Weight reduction in the long programmes flattens at roughly sixty to seventy-two weeks. The timing is consistent, predictable and almost never mentioned in advance.
Reading a barrel: the graduation that is not the one you think
We work through the arithmetic in full, because it is short, and because the errors it prevents are order-of-magnitude errors.
Rapid weight loss moves eight analytes for reasons that have nothing to do with the drug
Which movements are expected, which resolve, and which warrant investigation.
Background rates, and why they matter for attribution
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
The anatomy of the most reproduced page in this trade
The purity figure is the least informative line on a well-constructed certificate and the only line most buyers read.
Escalating past the approved maximum, examined honestly
Where the curve flattens, what flattens with it, and what does not.
Background rates, and why they matter for attribution
A small number of serious gastrointestinal events occur in people taking these drugs. Distinguishing them from the expected effect profile is the most consequential…
What a mass spectrometer does to a peptide before it measures anything
The ionisation method determines the charge states you see, the adducts you must account for, and the modifications you might destroy in the process.
The lowest effective dose is a real concept with almost no data behind it
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The intramuscular injection nobody intended
A 4 mm needle at ninety degrees without a skin pinch is adequate for essentially all adults. The persistence of 12.7 mm needles in this market is habit, not reasoning.
The isotope pattern tells you the charge, and the charge tells you the mass
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
Non-responders, and the honest state of the evidence about them
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
Vitamin D, adiposity, and a volume-of-distribution problem
Micronutrient guidance for this drug class is borrowed almost entirely from post-bariatric surveillance, where the anatomy is different and the deficiency mechanisms are not…